Ocean Biomedical Past Earnings Performance
Past criteria checks 0/6
Ocean Biomedical's earnings have been declining at an average annual rate of -301.5%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-301.5%
Earnings growth rate
-351.6%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Ocean Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 0 | -99 | 11 | 1 |
30 Jun 23 | 0 | -88 | 10 | 2 |
31 Mar 23 | 0 | -84 | 11 | 6 |
31 Dec 22 | 0 | -17 | 8 | 8 |
30 Sep 22 | 0 | -25 | 12 | 11 |
31 Mar 22 | 0 | -24 | 12 | 12 |
31 Dec 21 | 0 | -62 | 28 | 34 |
30 Sep 21 | 0 | -55 | 24 | 31 |
31 Mar 21 | 0 | -46 | 20 | 25 |
31 Dec 20 | 0 | -2 | 2 | 0 |
Quality Earnings: 8AW0 is currently unprofitable.
Growing Profit Margin: 8AW0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 8AW0's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 8AW0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8AW0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 8AW0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.